Ubs Asset Management Americas Inc Denali Therapeutics Inc. Transaction History
Ubs Asset Management Americas Inc
- $446 Billion
- Q3 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 5,465,037 shares of DNLI stock, worth $95.3 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
5,465,037
Previous 6,262,277
12.73%
Holding current value
$95.3 Million
Previous $87.6 Million
9.42%
% of portfolio
0.02%
Previous 0.02%
Shares
28 transactions
Others Institutions Holding DNLI
# of Institutions
260Shares Held
133MCall Options Held
219KPut Options Held
107K-
Black Rock Inc. New York, NY13.2MShares$230 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$209 Million0.0% of portfolio
-
Baillie Gifford & CO11.6MShares$202 Million0.13% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.64MShares$98.3 Million0.05% of portfolio
-
State Street Corp Boston, MA5.46MShares$95.3 Million0.0% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $2.34B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...